Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer

A recent study looked at the efficacy and safety of first-line treatment with a combination of immunotherapies (immune checkpoint inhibitors) for sarcomatoid renal cell carcinoma (RCC). The analysis included five clinical trials involving 568 patients with sarcomatoid RCC. All combinations that were looked at significantly improved progression-free survival and response rate. Combination treatments with nivolumab […]

read more

Risks and benefits of adjuvant therapy for kidney cancer

Treatment of people with intermediate to high risk renal cell carcinoma (RCC) with medicine to prevent the cancer from coming back (adjuvant therapy) can benefit some patients, but it’s important for each patient to weigh the treatment benefit and potential risk of side effects on quality of life. Adjuvant therapy has been shown to delay […]

read more

Immune cell patterns can help predict if kidney cancer patients will respond to immunotherapy

In a study published in Cancer Cell last week, researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumours that can help predict if patients with kidney cancer will respond to immunotherapy. The scientists looked at 115 tumour samples from 15 people with metastatic clear […]

read more

Radiotherapy instead of systemic therapy for metastatic kidney cancer

The use of radiotherapy for the treatment of metastatic renal cell carcinoma (RCC) is not routine. In a recent study, the use of radiotherapy to delay the use of medicines (systemic therapy) for patients with a small number of RCC metastases (oligometastatic) was assessed. There were 30 patient in the study, al of whom had […]

read more

First patient enrolled in renal cell carcinoma liquid biopsy trial

The first patient has been enrolled in the AURORAX-087A study involving a new liquid biopsy for the detection of recurrence after surgery for clear cell renal cell carcinoma (RCC), the most common form of kidney cancer. The study is taking place at 16 hospitals across Europe and the US, 6 of which are in the […]

read more

Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients

A recent study published in Journal of Clinical Medicine this month reports the real-world incidence of immune-related side effects associated with nivolumab plus ipilimumab in patients with renal cell carcinoma (RCC). This observational study looked at the incidence and severity of immune-related side effects in 41 patients taking nivolumab plus ipilimumab for the treatment of […]

read more

Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. Also, patients with brain metastases from RCC are not allowed in most clinical trials, and there is an unmet need for treatment of […]

read more

PARP1 as a potential biomarker for response to immunotherapy

In a recent study, the researchers looked at the RNA in renal cell carcinoma (RCC) tissue samples from patients being treated with immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, avelumab) to try to identify a biomarker for response to treatment. They found that patients with low levels of a protein-coding gene called PARP1 (poly (ADP-ribose) polymerase […]

read more

Survival after nephrectomy for various kidney cancer subtypes

Data presented at the American Urological Association (AUA) 2021 meeting last month shows that 5-year survival rates following partial or radical nephrectomy for renal cell carcinoma (RCC) vary depending on the histology of the RCC subtype. The results of this study have implications for developing personalised therapies to target high-risk, aggressive tumours. The researchers identified […]

read more

SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more
Showing 11 to 20 of 829 results
  TOP